Genetic Signatures will exhibit at the 16th Asia-Pacific Congress of Clinical Microbiology and Infection (APCCMI) in Melbourne, Australia on 30 November – 3 December 2016. Genetic Signatures will be exhibiting their EasyScreen products for the detection of infectious diseases, including kits for diagnosing bacterial, viral and protozoan causes of gastroenteritis direct from faeces, and the causes…

Genetic Signatures to present its global growth strategy for the development and supply of world leading molecular diagnostic products  The largest conference in Australia focused on microcap investment opportunities  Presentations from the CEOs of 24 of Australia’s leading emerging companies  Molecular Diagnostic (MDx) company Genetic Signatures (ASX: GSS) is pleased to release a copy of…

Genetic Signatures EasyScreen™ Pathogen Detection Kits will be featured in two oral presentations at the upcoming NRL Workshop on Molecular Diagnostics in Melbourne, Australia. The NRL Molecular Workshop is a forum for scientists, regulators, test kit manufacturers and clinicians to unite and discuss current issues and new technologies occurring in the world of molecular pathology…

A recent publication in Veterinary Parasitology by Chan et al. “Detection of Dientamoeba fragilis in animal faeces using species-specific real-time PCR assay” has shown that the EasyScreen™ Enteric Protozoan Detection Kit shows superior specificity detecting Dientamoeba fragilis in animal faeces. The EasyScreen™ kit was compared to two previously published PCR methods. The two previously published PCR methods…

A recent publication by Shin, Chaves-Olarte, and Warren has described the global epidemiology of Clostridium difficile infection (CDI) as well as new approaches in management, including fecal microbiota transplantation. The publication cites a 2014 study by Magill SS et al that reported that CDI is the most common cause of health care–associated infections in the United States…

GenomeWeb, the largest online newsroom focused on advanced molecular research tools, recently featured Genetic Signatures in an article about the company’s global expansion strategy. The article highlighted the company’s recent launch of Analyte-Specific Reagents in the US and plans to gain FDA approval for its MDx panels. Also discussed was the company’s novel multiplex PCR…

UCLA successfully completes Genetic Signatures product trial Study demonstrates GSS 3Base™ technology & products as globally impactful Trial results to be officially published by UCLA Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that the University of California, Los Angeles (UCLA) has notified the Company that a recent GSS product evaluation…

The directors and staff of Genetic Signatures Ltd wish to congratulate our board member, Dr Anthony Radford, on being awarded Queens Birthday Honours.  Dr. Radford received the Officer of the Order of Australia for distinguished service to science and global public health through innovation, research and development of technology to diagnose tuberculosis.

19 May 2016 – The Age: Superbugs will kill 10 million people a year by 2050 This recent article published in The Age describes a call to action from Britain’s chancellor, George Osborne, to the finance ministers from around the world, to agree on a common approach to fight the threat of antibiotic-resistant bacteria at the September…

Dr. Doug Millar, Genetic Signatures Chief Scientific Officer, presented a scientific poster titled “A Rapid 3base™ Real-Time PCR for the detection of Extended Spectrum Beta-Lactamase and Carbapenemase-Producing Organisms using Multi-Coloured Fluorogenic Probes“ at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. The data presented showed that the Genetic Signatures…